Danaher Co. (NYSE:DHR) Shares Bought by FSM Wealth Advisors LLC

FSM Wealth Advisors LLC lifted its holdings in Danaher Co. (NYSE:DHR) by 4.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,068 shares of the conglomerate’s stock after acquiring an additional 226 shares during the period. FSM Wealth Advisors LLC’s holdings in Danaher were worth $1,205,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Fairfield Bush & CO. grew its holdings in Danaher by 10.9% during the 1st quarter. Fairfield Bush & CO. now owns 4,840 shares of the conglomerate’s stock worth $1,420,000 after acquiring an additional 475 shares in the last quarter. Zions Bancorporation N.A. increased its position in shares of Danaher by 19.3% in the 1st quarter. Zions Bancorporation N.A. now owns 2,468 shares of the conglomerate’s stock worth $724,000 after purchasing an additional 400 shares during the last quarter. Covestor Ltd increased its position in shares of Danaher by 76.8% in the 1st quarter. Covestor Ltd now owns 495 shares of the conglomerate’s stock worth $145,000 after purchasing an additional 215 shares during the last quarter. NewEdge Advisors LLC increased its position in shares of Danaher by 14.1% in the 1st quarter. NewEdge Advisors LLC now owns 31,530 shares of the conglomerate’s stock worth $9,248,000 after purchasing an additional 3,897 shares during the last quarter. Finally, Bridgewater Associates LP increased its position in shares of Danaher by 135.9% in the 1st quarter. Bridgewater Associates LP now owns 35,270 shares of the conglomerate’s stock worth $10,346,000 after purchasing an additional 20,320 shares during the last quarter. Institutional investors and hedge funds own 76.71% of the company’s stock.

Insider Transactions at Danaher

In related news, SVP Daniel Raskas sold 11,213 shares of the stock in a transaction dated Friday, July 28th. The shares were sold at an average price of $260.65, for a total transaction of $2,922,668.45. Following the completion of the sale, the senior vice president now owns 38,288 shares in the company, valued at approximately $9,979,767.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Jose-Carlos Gutierrez-Ramos sold 590 shares of Danaher stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $250.54, for a total transaction of $147,818.60. Following the completion of the sale, the senior vice president now owns 6,939 shares in the company, valued at approximately $1,738,497.06. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Daniel Raskas sold 11,213 shares of Danaher stock in a transaction that occurred on Friday, July 28th. The stock was sold at an average price of $260.65, for a total transaction of $2,922,668.45. Following the transaction, the senior vice president now directly owns 38,288 shares in the company, valued at approximately $9,979,767.20. The disclosure for this sale can be found here. In the last three months, insiders sold 47,922 shares of company stock valued at $12,552,233. Company insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the subject of a number of recent research reports. Raymond James boosted their price objective on shares of Danaher from $270.00 to $290.00 and gave the company an “outperform” rating in a research report on Wednesday, July 26th. Bank of America upped their target price on shares of Danaher from $250.00 to $280.00 in a research report on Wednesday, July 26th. Royal Bank of Canada upped their target price on shares of Danaher from $260.00 to $292.00 in a research report on Wednesday, July 26th. Stifel Nicolaus cut their target price on shares of Danaher from $250.00 to $240.00 and set a “hold” rating for the company in a research note on Wednesday, July 26th. Finally, StockNews.com assumed coverage on shares of Danaher in a research note on Tuesday, September 12th. They set a “hold” rating for the company. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $289.79.

Danaher Stock Performance

Danaher stock traded down $0.15 during mid-day trading on Monday, reaching $255.10. The company had a trading volume of 689,874 shares, compared to its average volume of 2,864,582. The company has a 50 day moving average of $253.41 and a 200-day moving average of $245.09. The firm has a market cap of $188.35 billion, a price-to-earnings ratio of 29.92, a PEG ratio of 2.73 and a beta of 0.80. Danaher Co. has a 52 week low of $221.22 and a 52 week high of $283.63. The company has a quick ratio of 1.70, a current ratio of 2.08 and a debt-to-equity ratio of 0.35.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 25th. The conglomerate reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.04. The company had revenue of $7.16 billion during the quarter, compared to the consensus estimate of $7.12 billion. Danaher had a net margin of 20.95% and a return on equity of 15.03%. The firm’s revenue for the quarter was down 7.7% compared to the same quarter last year. During the same period last year, the firm earned $2.76 EPS. On average, sell-side analysts expect that Danaher Co. will post 8.84 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Thursday, October 12th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date is Wednesday, October 11th. Danaher’s payout ratio is 12.68%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions.